Treatment with ramipril reduces left ventricular mass in asymptomatic patients with aortic stenosis (RIAS trial) Discussion: Bull S., Loudon M., Francis J.M. et al.: A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). European Heart Journal – Cardiovascular Imaging 2015; 16: 834-841 [doi: 10.1093/ehjci/jev043].
Article Sidebar
Published:
Sep 30, 2016
Keywords:
ramipril, left ventricular hypertrophy, aortic stenosis
Main Article Content
Abstract
Left ventricular hypertrophy is a complication of hypertension and aortic stenosis. Authors of RIAS trial demonstrate that treatment with ramipril significantly reduces left ventricular mass in asymptomatic patients with moderate to severe aortic stenosis.
Article Details
How to Cite
Cacko, A. (2016). Treatment with ramipril reduces left ventricular mass in asymptomatic patients with aortic stenosis (RIAS trial). Medycyna Faktow (J EBM), 9(3(32), 267-270. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2237
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio- Thoracic Surgery (EACTS): Vahanian A., Alfieri O., Andreotti F. et al.: Guidelines on the management of valvular heart disease (version 2012). Eur. Heart J. 2012; 33(19): 2451-2496.
2. Baranowski R., Wojciechowski D., Kozłowski D. et al.: Compendium for performing and describing the resting electrocardiogram. Diagnostic criteria describe rhythm, electrical axis of the heart, QRS voltage, automaticity and conduction disorders. Experts‘ group statement of the Working Group on Noninvasive Electrocardiology. Kardiol. Pol. 2016; 74(5): 493-500.
3. Haider A.W., Larson M.G., Benjamin E.J., Levy D.: Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J. Am. Coll. Cardiol. 1998; 32(5): 1454-1459.
4. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Kardiol. Pol. 2015; 73(8): 676-700.
5. Verdecchia P., Carini G., Circo A. et al.: Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J. Am. Coll. Cardiol. 2001; 38(7): 1829-1835.
6. Franz I.W., Tönnesmann U., Müller J.F.: Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am. J. Hypertens. 1998; 11(6 Pt 1): 631-639.
7. Lièvre M., Guéret P., Gayet C. et al.: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Hypertension. 1995; 25(1): 92-97.
8. Klingbeil A.U., Schneider M., Martus P. et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 2003; 115(1): 41-46.
2. Baranowski R., Wojciechowski D., Kozłowski D. et al.: Compendium for performing and describing the resting electrocardiogram. Diagnostic criteria describe rhythm, electrical axis of the heart, QRS voltage, automaticity and conduction disorders. Experts‘ group statement of the Working Group on Noninvasive Electrocardiology. Kardiol. Pol. 2016; 74(5): 493-500.
3. Haider A.W., Larson M.G., Benjamin E.J., Levy D.: Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J. Am. Coll. Cardiol. 1998; 32(5): 1454-1459.
4. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Kardiol. Pol. 2015; 73(8): 676-700.
5. Verdecchia P., Carini G., Circo A. et al.: Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J. Am. Coll. Cardiol. 2001; 38(7): 1829-1835.
6. Franz I.W., Tönnesmann U., Müller J.F.: Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am. J. Hypertens. 1998; 11(6 Pt 1): 631-639.
7. Lièvre M., Guéret P., Gayet C. et al.: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Hypertension. 1995; 25(1): 92-97.
8. Klingbeil A.U., Schneider M., Martus P. et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 2003; 115(1): 41-46.